Recurrent Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Recurrent ovarian cancer is characterized by the return of the tumor after a complete initial response to first-line chemotherapy, a negative second-look laparotomy (if performed), and a disease-free interval of more than six months. Approximately 87% of recurrences occur within five years of the primary treatment, with 21% happening within the first year. The most common relapse sites include pelvic masses (48%), peritoneal disease (45%), large or small bowel serosal disease (45%), and nodal disease, particularly in the paraaortic region (33%). Unusual recurrence sites include the brain, muscles, spleen, and biliary system. Bowel symptoms are frequent in these cases. The primary goal of treatment for recurrent ovarian cancer is to prolong symptom-free survival and palliate symptoms. Patients are categorized by their “platinum sensitivity,” which is determined by the length of the treatment-free interval. Those whose disease progresses during therapy or recurs within six months of completing treatment are considered “platinum-resistant,” typically showing low response rates and short survival times. Currently, there are no defined selection criteria for surgery in patients with recurrent ovarian cancer.

Thelansis’s “Recurrent Ovarian Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Ovarian Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Recurrent Ovarian Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Recurrent Ovarian Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Recurrent Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033